Fractalkine’s involvement in neurodegeneration has been relatively controversial, with disruption of fractalkine signaling being beneficial in some disease states (amyloid pathology and stroke) and yet detrimental in other neurodegenerative diseases (PD, ALS, and tauopathies). The gene discussed is CX3CL1; the disease is neurodegenerative disease.